Skip to main content
. 2017 Dec 3;2017:1683060. doi: 10.1155/2017/1683060

Table 2.

Summary of data in the metastatic setting.

Author (year) Line of treatment
Type of trial
Drug(s) Number of patients evaluable for end points Results
Yoshimoto et al. [11] 1st-2nd line
Phase II
CAPE 828 mg/m2 twice daily + CTX 33 mg/m2 twice daily, dd 1 → 14, every 21 days 9 ORR 44.4%
CBR 57.8%
Median PFS 10.7 months

Wang et al. [12] 2nd line or further
(maintenance)
Phase II
CTX 50 mg daily (after CTX 3 g/m2 for the preparation of CD34+ and CTX 3 g/m2, thiotepa 150 mg/m2, and CBDCA AUC = 6, every 28 dd for 2 courses) 23 NA

Kummar et al. [13] 2nd line or further
Phase II
CTX 50 mg/day
versus
CTX 50 mg/day + Veliparib 60 mg once daily throughout a 21-day cycle
39 ORR 5.6% versus 9.5%
(NS)

ORR = overall response rate; CBR = clinical benefit rate; PFS = progression-free survival; CBDCA = carboplatin.